Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant axitinib + avelumab for localized renal cell carcinoma at moderate to high risk of recurrence
NL-OMON59504Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and avelumab in renal cell carcinoma (RCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of partial remission. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
axitinibavelumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON59504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59504.